Arvinas (NASDAQ:ARVN) CEO Randy Teel Sells 4,786 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO Randy Teel sold 4,786 shares of the stock in a transaction that occurred on Monday, February 23rd. The stock was sold at an average price of $12.16, for a total transaction of $58,197.76. Following the completion of the transaction, the chief executive officer owned 149,696 shares in the company, valued at $1,820,303.36. The trade was a 3.10% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Randy Teel also recently made the following trade(s):

• On Friday, February 13th, Randy Teel sold 4,403 shares of Arvinas stock. The stock was sold at an average price of $11.89, for a total value of $52,351.67.

Arvinas Trading Up 7.5%

Arvinas stock traded up $0.93 during trading on Wednesday, reaching $13.30. The company had a trading volume of 1,374,807 shares, compared to its average volume of 820,559. The firm has a market capitalization of $854.13 million, a price-to-earnings ratio of -16.42 and a beta of 1.88. The firm’s 50-day simple moving average is $12.37 and its 200 day simple moving average is $10.51. Arvinas, Inc. has a 52 week low of $5.90 and a 52 week high of $18.93.

Arvinas (NASDAQ:ARVN) last released its quarterly earnings results on Tuesday, February 24th. The company reported ($1.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.55) by ($0.55). Arvinas had a negative net margin of 18.73% and a negative return on equity of 9.77%. The company had revenue of $9.50 million for the quarter, compared to the consensus estimate of $37.26 million. During the same period in the prior year, the firm posted ($0.63) EPS. The business’s revenue for the quarter was down 84.0% on a year-over-year basis. On average, analysts predict that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have weighed in on ARVN. BTIG Research upped their price target on shares of Arvinas from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Thursday, October 30th. Weiss Ratings restated a “sell (d-)” rating on shares of Arvinas in a research note on Monday, December 22nd. Citigroup upgraded Arvinas from a “neutral” rating to a “buy” rating and increased their price target for the stock from $10.00 to $15.00 in a research note on Tuesday, January 6th. Wells Fargo & Company decreased their price target on Arvinas from $16.00 to $15.00 and set an “overweight” rating on the stock in a report on Thursday, November 6th. Finally, Barclays boosted their price objective on Arvinas from $16.00 to $18.00 and gave the company an “overweight” rating in a research report on Wednesday, December 17th. Ten investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Arvinas presently has a consensus rating of “Hold” and a consensus price target of $13.47.

Arvinas News Roundup

Here are the key news stories impacting Arvinas this week:

• Positive Sentiment: Company emphasizes multiple 2026 clinical data catalysts (ARV‑102 LRRK2 Phase 1 Parkinson’s readout accepted for AP/PD; ARV‑806 and ARV‑393 data on track; ARV‑027 Phase 1 initiated; ARV‑6723 (HPK1 degrader) expected to start Phase 1 mid‑2026) and says cash runway extends into the second half of 2028 — these milestone timelines give investors potential near‑term value drivers. Arvinas Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
• Positive Sentiment: Seeking Alpha summary highlights the company’s 2026 clinical data milestones and strategic pipeline focus, reinforcing the narrative that upcoming readouts could be value‑creating despite current revenue weakness. Arvinas outlines 2026 clinical data milestones and maintains cash runway
• Positive Sentiment: Piper Sandler reaffirmed an “overweight” rating and raised its price target to $20 from $16 (implying substantial upside from current levels), which likely supported buying interest from growth/clinical‑stage biotech investors. Piper Sandler rating/price target report
• Positive Sentiment: Market commentary notes ARVN moving higher in Nasdaq futures due to the promising pipeline and upcoming data cadence, reflecting market focus on clinical catalysts over near‑term revenue. Arvinas Moves Higher In Nasdaq Futures With Promising Pipeline
• Neutral Sentiment: Aggregated analyst coverage remains mixed — Arvinas has an average “Hold” rating from analysts, indicating not all brokers are convinced the pipeline alone justifies a buy consensus. Arvinas Given Average Rating of Hold
• Negative Sentiment: Q4 2025 results were a clear miss: EPS of ($1.10) vs. consensus ($0.55) and revenue of $9.5M vs. $37.26M expected (revenue down ~84% YoY). The large shortfall increases near‑term execution risk and keeps the company loss‑making, which is a headwind for valuation until clinical proof points arrive. Arvinas Reports Q4 Loss, Misses Revenue Estimates

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Monaco Asset Management SAM grew its holdings in Arvinas by 185.6% during the 2nd quarter. Monaco Asset Management SAM now owns 900,936 shares of the company’s stock valued at $6,631,000 after buying an additional 585,477 shares in the last quarter. Acadian Asset Management LLC boosted its position in shares of Arvinas by 791.1% during the 2nd quarter. Acadian Asset Management LLC now owns 1,427,832 shares of the company’s stock valued at $10,498,000 after acquiring an additional 1,267,593 shares during the last quarter. Campbell & CO Investment Adviser LLC grew its holdings in shares of Arvinas by 307.7% in the third quarter. Campbell & CO Investment Adviser LLC now owns 223,576 shares of the company’s stock valued at $1,905,000 after purchasing an additional 168,744 shares in the last quarter. Nordea Investment Management AB grew its holdings in shares of Arvinas by 28.7% in the third quarter. Nordea Investment Management AB now owns 557,742 shares of the company’s stock valued at $4,730,000 after purchasing an additional 124,254 shares in the last quarter. Finally, SG Americas Securities LLC bought a new stake in Arvinas in the second quarter worth $390,000. Hedge funds and other institutional investors own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc (NASDAQ: ARVN) is a biopharmaceutical company focused on the development of therapies based on targeted protein degradation. Utilizing its proprietary proteolysis-targeting chimera (PROTAC®) platform, Arvinas aims to selectively eliminate disease-causing proteins rather than merely inhibit their activity. This novel approach has the potential to address a range of diseases, including oncology, neurodegeneration and inflammation, by harnessing the body’s natural protein-recycling systems.

The company’s most advanced clinical candidates address hormone-driven cancers.